Top View
- Rucaparib for Advanced BRCA-Mutated Ovarian Cancer
- | Oral Chemotherapy Monitoring & Counseling
- Study Protocol: CO-338-085
- Appendix B - Product Name Sorted by Applicant
- PARP Inhibitors As Therapeutics: Beyond Modulation of Parylation
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- Stabilization of Mutant BRCA1 Protein Confers PARP Inhibitor and Platinum Resistance
- Oncology Oral, Other Therapeutic Class Review
- Activity of Trabectedin and the PARP Inhibitor Rucaparib in Soft-Tissue
- (COMP) Meeting Report on the Review of Applications for Orphan Designation December 2016
- Rubraca (Rucaparib) Treatment of Ovarian Cancer EU/3/12/1049 (EMA/OD/085/12) Sponsor: Clovis Oncology UK Limited
- Clinically Relevant Concentrations of Anticancer Drugs: a Guide for Nonclinical Studies Dane R
- The HRD Decision--Which PARP Inhibitor to Use for Whom and When
- Adult Antiemetic Management of Chemotherapy-Induced Nausea
- Open Full Page
- State and Specialty Pharmacy Drug Reimbursement Rates
- Strategies for the Improvement of Metal-Based Chemotherapeutic Treatments
- A Phase I Study of Intravenous and Oral Rucaparib in Combination with Chemotherapy in Patients with Advanced Solid Tumours
- Emetogenic Potential of Antineoplastic Agents
- Combination Treatment with Rucaparib (Rubraca) and MDM2 Inhibitors, Nutlin-3 and RG7388, Has Synergistic and Dose Reduction Potential in Ovarian Cancer
- Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers
- Intracranial Evaluation of the in Vivo Pharmacokinetics, Brain
- Oncology Proposal
- YTD September 2020 Sales
- List of Cleared Or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)
- Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
- Multifaceted Role of PARP-1 in DNA Repair and Inflammation
- WO 2014/152330 Al 25 September 2014 (25.09.2014) P O P C T
- 211651Orig1s000
- Public Assessment Reports
- PARP Inhibition and Synthetic Lethality in Ovarian Cancer
- Pharmacology Update
- Table of Pharmacogenomic Biomarkers in Drug Labeling Last Updated: 06/2018
- BKM120 Sensitizes Glioblastoma to the PARP Inhibitor Rucaparib By
- PARP Inhibitors: the Race Is On
- Summary of Risk Management Plan for Rubraca (Rucaparib)
- Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy
- Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
- Standard Oncology Criteria Policy Number: Pending
- Novel Insights Into the Immunotherapy of Soft Tissue Sarcomas: Do We Need a Change of Perspective?
- Immunotherapy in Advanced Prostate Cancer
- STAMPEDE Systemic Therapy in Advancing Or
- FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
- Efficacy and Safety of Rucaparib in Previously Treated, Locally Advanced Or Metastatic Urothelial Carcinoma from a Phase 2, Open-Label Trial (ATLAS) P
- (PDOX) Nude Mouse Model
- Hyperthermia Synergizes with Chemotherapy by Inhibiting PARP1-Dependent DNA
- Immunotherapy As a Precision Medicine Tool for the Treatment of Prostate Cancer
- Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited By
- E-Learning Treatment for Relapsing Platinum Sensitive Epithelial
- Smart Approaches for the Effective Treatment of Breast Cancer
- Rucaparib (Rubraca) Reference Number: ERX.SPA.11 Effective Date: 04.01.17 Last Review Date: 02.21 Line of Business: Commercial, Medicaid Revision Log
- Do Not Tube List
- • on September 24, the Food and Drug Administration (FDA
- Rucaparib (Rubraca) Forplatinum-Sensitive, High
- (A) Carboplatin, (B) Doxorubicin, (C) Gemcitabine, (D) Topotecan, (E) Paclitaxel, and (F) Rucaparib, Across the Cell Line Panel
- Rucaparib Vs Chemotherapy in Patients With
- Rubraca, INN-Rucaparib Camsylate
- Rubraca® (Rucaparib) P&T Approval Date 10/2019, 10/2020 Effective Date 2/1/2021; Oxford Only: 2/1/2021
- November 2020
- Rubraca (Rucaparib) Tablets Contain Rucaparib Camsylate As the Active Ingredient
- FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation–Associated Advanced Ovarian Cancer Sanjeeve Balasubramaniam1, Julia A